Hepion Pharmaceuticals, Inc. is a forward-thinking biopharmaceutical company based in Edison, New Jersey, dedicated to developing innovative therapies for chronic liver diseases, with a primary focus on non-alcoholic steatohepatitis (NASH). The company boasts a strong pipeline and advanced drug discovery platforms, positioning it as a key player in addressing significant unmet needs within hepatology. Its lead candidate, CRV431, shows substantial potential in treating liver-related conditions, highlighting Hepion's commitment to enhancing patient outcomes and its strategic importance in the expanding liver therapeutics market. Show more

Location: 55 MADISON AVENUE, MORRISTOWN, NJ, UNITED STATES, 07960, Morristown, NJ, 07960, USA | Website: https://hepionpharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

766.9K

52 Wk Range

$0.11 - $11.26

Previous Close

$0.04

Open

$0.04

Volume

1,289

Day Range

$0.03 - $0.04

Enterprise Value

53.17K

Cash

2.924M

Avg Qtr Burn

-1.375M

Insider Ownership

0.00%

Institutional Own.

0.05%

Qtr Updated

06/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
HEPA-CRV431-210 (rencofilstat) Details Non-alcoholic steatohepatitis , Hepatitis B	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HEPA-CRV431-207 (rencofilstat) Details Hepatitis B, Non-alcoholic steatohepatitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.